Businesstoday iconBusinesstodaySep 7, 2026

Mounjaro Sales Surge 502%: Why GLP-1 Drugs Are Taking Over India’s Pharma Market

India's pharma market is witnessing a major shift as diabetes and weight-management therapies gain rapid traction. PharmaTrac's August 2026 data shows the overall pharma market grew 10.4%, while the antidiabetic segment rose 15.2% in value.

Mounjaro Sales Surge 502%: Why GLP-1 Drugs Are Taking Over India’s Pharma Market
Read original More from Businesstoday

Share this story

Send the public story page.

Useful takeaways from this story.

India's pharma market is witnessing a major shift as diabetes and weight-management therapies gain rapid traction.

PharmaTrac's August 2026 data shows the overall pharma market grew 10.4%, while the antidiabetic segment rose 15.2% in value.

Mounjaro emerged as the country's top-selling brand, with MAT sales reaching ₹1,256 crore, up 502%.

Building the complete brief

The page is ready to read now. The fuller skim-friendly version will appear here automatically.

The useful part

India's pharma market is witnessing a major shift as diabetes and weight-management therapies gain rapid traction. PharmaTrac's August 2026 data shows the overall pharma market grew 10.4%, while the antidiabetic segment rose 15.2% in value. Mounjaro emerged as the country's top-selling brand, with MAT sales reaching ₹1,256 crore, up 502%.

How it works

  • Business Today's Neetu Chandra Sharma explains the rising demand for GLP-1 drugs and the growing awareness around diabetes and obesity treatments.
  • Abhishek Basumallick, Co-founder & Fund Manager, Shree Rama Managers, remains positive on pharma, citing the potential of GLP-1 therapies and upcoming patent expiries as major opportunities for Indian...

Keep reading in the app

Open the app view to save this story, compare related coverage, and continue from the same source.

Open in app